Gsk (GLAXF) Minority Interest (2009 - 2026)

Gsk's Minority Interest history runs 18 years deep, the most recent figure standing at -$579.7 million for Q1 2026.

• In Q1 2026, Minority Interest rose 8.49% year-over-year to -$579.7 million; the TTM figure through Mar 2026 stood at -$579.7 million (up 8.49% YoY), while the FY2025 annual figure was -$555.1 million, up 25.77% from the prior year.
• Minority Interest was -$579.7 million for Q1 2026 at Gsk, down from -$560.0 million in the prior quarter.
• In the past five years, Minority Interest ranged from a high of $8.7 billion in Q1 2022 to a low of -$775.1 million in Q1 2024.
• Historically, Minority Interest has averaged $407.5 million across 5 years, with a median of -$617.5 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Minority Interest tumbled 108.44% in 2023, then advanced 25.9% in 2025.
• A 5-year view of Minority Interest shows it stood at -$588.8 million in 2022, then dropped by 16.36% to -$685.1 million in 2023, then retreated by 9.59% to -$750.8 million in 2024, then gained by 25.42% to -$560.0 million in 2025, then decreased by 3.52% to -$579.7 million in 2026.
• The last three Minority Interest figures came in at -$579.7 million (Q1 2026), -$560.0 million (Q4 2025), and -$534.3 million (Q3 2025), per Business Quant data.